LinkedIn Profile

Access Adaptimmune Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Ticker Sector Ticker Industry
nasdaq:adap 9045855 Jul 20th, 2019 12:00AM Adaptimmune 10K 373.00 Open Biotechnology Jul 20th, 2019 03:01PM Jul 20th, 2019 03:01PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 19th, 2019 12:00AM Adaptimmune 10K 374.00 Open Biotechnology Jul 18th, 2019 10:05PM Jul 18th, 2019 10:05PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 18th, 2019 12:00AM Adaptimmune 10K 374.00 Open Biotechnology Jul 18th, 2019 12:49PM Jul 18th, 2019 12:49PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 17th, 2019 12:00AM Adaptimmune 10K 374.00 Open Biotechnology Jul 17th, 2019 08:27AM Jul 17th, 2019 08:27AM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 16th, 2019 12:00AM Adaptimmune 10K 373.00 Open Biotechnology Jul 16th, 2019 09:26AM Jul 16th, 2019 09:26AM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 15th, 2019 12:00AM Adaptimmune 10K 372.00 Open Biotechnology Jul 14th, 2019 10:05PM Jul 14th, 2019 10:05PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 14th, 2019 12:00AM Adaptimmune 10K 372.00 Open Biotechnology Jul 14th, 2019 01:32PM Jul 14th, 2019 01:32PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 13th, 2019 12:00AM Adaptimmune 10K 373.00 Open Biotechnology Jul 12th, 2019 10:05PM Jul 12th, 2019 10:05PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 12th, 2019 12:00AM Adaptimmune 10K 374.00 Open Biotechnology Jul 12th, 2019 01:06PM Jul 12th, 2019 01:06PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jul 11th, 2019 12:00AM Adaptimmune 10K 374.00 Open Biotechnology Jul 10th, 2019 10:05PM Jul 10th, 2019 10:05PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.